Celebrex Database Clear Of Cardiovascular Signals, FDA’s Woodcock Says

Data safety monitoring boards for ongoing prevention trials with Pfizer’s Celebrex say there is no indication the trials should be stopped. However, FDA is hesitant to make a final determination on Celebrex safety. The safety profile for Pfizer’s Bextra also is inconclusive, Woodcock says.

Pink Sheet Podcast

Learn what's happening at the US FDA. On the go.

Derrick Gingery and the team bring you a weekly "Drug Fix".

More from Archive

More from Pink Sheet